Skip to main content

From three to 16: TD Bank significantly increases how many cannabis stocks its advisers can recommend

Part of cannabis and investing

Toronto-Dominion Bank is getting more comfortable with the cannabis sector.

The bank made an unusual move in April to restrict how its investment advisers could talk to clients about the burgeoning industry, banning staff from recommending all but three Canadian pot stocks. At the time, TD said it approved medical marijuana growers Canopy Growth Corp., Emerald Health Therapeutics Inc. and Emblem Corp. because they don’t have any exposure to the United States, where the drug is prohibited under federal law but legal in certain states.

TD has been reviewing the space and is now adding 16 more cannabis firms to its approved list of equities, including Cronos Group Inc. and CannTrust Holdings Inc., according to a June 27 e-mail sent to advisers. Five of these companies are listed on the Toronto Stock Exchange and 11 are listed on the TSX Venture Exchange.

Story continues below advertisement

In order to be included on TD’s “eligible for solicitation list,” an issuer must be listed on the TSX or the TSXV and can’t have any prohibited U.S. touchpoints as determined by the bank, TD spokesman Paolo Pasquini said.

In October, TMX Group Ltd., the largest operator of stock markets in Canada, clarified its policy to restrict any cannabis company violating U.S. federal law from listing on the TSX or TSXV. The markets conducted a review of their issuers, forcing those breaching the policy to offload their U.S. assets to keep their listing. TMX has more than two dozen pot stocks listed on the TSX and TSXV, including Aurora Cannabis Inc. and Aphria Inc.

But advisers in the TD Wealth Private Investment Advice (PIA) network are still not permitted to recommend shares of Aurora and Aphria, two of Canada’s largest cannabis growers, nor the four Canadian marijuana exchange-traded funds (ETFs).

Aurora said in June that it was spinning out its U.S. assets and applying to list that company – named Australis Capital Inc. – on the Canadian Securities Exchange, where looser listing rules than the bigger TSX have seen it become home for many pot companies. Australis owns land in the state of Washington, where cannabis is legal for medical and recreational use, and has an interest in a Michigan company that has applied with the state to become a fully licensed medical grower.

Aphria has begun offloading its U.S. holdings, divesting its stake in an Arizona grower in February and selling a quarter of its equity stake in Florida’s Liberty Health Sciences Inc. The rest of its Liberty shares are being held in escrow and will be sold to the same buyers once a lock-up period ends and they become free trading.

Canada’s largest pot ETF – the Horizons Marijuana Life Sciences Index ETF (HMMJ) – has more than $796-million in assets under management and aims to track the North American Marijuana Index. HMMJ only includes 40 of the 49 stocks (including Aurora and Aphria) as it does not include those companies primarily focused on serving the medical or recreational marijuana market in the United States. Despite the fund listing this constraint, it does not appear on TD’s recommendation list.

TD would not answer specific questions about the approval process for its list, but Mr. Pasquini said “the cannabis industry is complex and evolving rapidly. As a result, TD has policies in place to manage the advice we provide to clients about investing in companies in this sector. Our most recent update reflects our ongoing evaluation of this emerging market. We expect our views will continue to evolve and develop with the industry.”

Story continues below advertisement

TD Wealth PIA serves clients with more than $750,000 in investable assets. The unit has more than 740 advisers, of which 200 are discretionary portfolio managers, meaning their clients defer individual investment decisions to them.

If a PIA client tells his or her adviser to buy shares of any marijuana firm or ETF, the adviser is allowed to make the trade. But if a client says they’re interested in the marijuana sector as a possible investment, a TD adviser can only recommend a stock that has been added to the approved list.

Last month, Parliament lifted the 95-year-old prohibition on cannabis and regulated the non-medical use of the drug, freeing millions of adults to use marijuana when the law comes into effect on Oct. 17.

As with any emerging sector, investments in legal marijuana businesses are risky. Most of the companies are startups and have booked little to no revenue. Yet, many investors are upbeat about their prospects, pouring millions into the sector despite the many unknowns – all in the hopes of cashing in on the green rush as countries around the world legalize and regulate cannabis.

Here’s the full list of pot stocks that TD has approved:

Canopy Growth Corp. -WEED

Story continues below advertisement

Emblem Corp. -EMC

Emerald Health Therapeutics -EMH

Cronos Group Inc. -CRON

Naturally Splendid Ent Ltd. -NSP

Weedmd Inc. - WMD

Tetra Bio-Pharma Inc. -TBP

Supreme Cannabis Co. Inc. -FIRE

Medreleaf Corp. -LEAF

Hydropothecary Corp.-HEXO

Abcann Global Corp. -ABCN

Newstrike Resources Ltd. -HIP

ICC Labs Inc. -ICC

Harvest One Cannabis Inc. -HVT

Delta 9 Cannabis Inc. -NINE

National Access Cannabis Corp. -META

CBD Med Research Corp. -CBM/H

Neptune Technologies & Bioress -NEPT

Canntrust Holdings Inc. -TRST

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter